Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

H.C. Wainwright Keeps Their Buy Rating on Xenon (XENE)

Tipranks - Tipranks - Mon Mar 16, 9:25PM CDT

In a report released yesterday, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Xenon, with a price target of $74.00.

Claim 70% Off TipRanks Premium

According to TipRanks, Tsao is a 5-star analyst with an average return of 17.4% and a 47.89% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Argenx Se, and Hansa Biopharma AB.

In addition to H.C. Wainwright, Xenon also received a Buy from Deutsche Bank ‘s David Hoang in a report issued on March 10. However, on March 13, TipRanks – xAI reiterated a Hold rating on Xenon (NASDAQ: XENE).

See Insiders’ Hot Stocks on TipRanks >>

Based on Xenon’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $105.26 million. In comparison, last year the company had a GAAP net loss of $65.69 million

Read More on XENE:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).